Poseida Therapeutics Target of Unusually High Options Trading (NASDAQ:PSTX)

Poseida Therapeutics, Inc. (NASDAQ:PSTX) saw unusually large options trading activity on Tuesday. Traders purchased 5,174 put options on the company. This represents an increase of 3,372% compared to the typical daily volume of 149 put options.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PSTX. Bayesian Capital Management LP acquired a new position in shares of Poseida Therapeutics during the first quarter worth approximately $33,000. Marshall Wace LLP acquired a new position in Poseida Therapeutics during the 2nd quarter worth $31,000. Rothschild Investment LLC bought a new position in shares of Poseida Therapeutics in the second quarter worth $35,000. Principal Financial Group Inc. bought a new stake in shares of Poseida Therapeutics during the second quarter valued at about $35,000. Finally, Virtu Financial LLC acquired a new stake in Poseida Therapeutics in the third quarter worth about $37,000. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Stock Up 228.0 %

PSTX stock opened at $9.38 on Wednesday. The stock has a market cap of $914.17 million, a PE ratio of -14.89 and a beta of 0.54. The firm’s 50-day simple moving average is $2.90 and its 200 day simple moving average is $2.97. Poseida Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $9.41. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on PSTX. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 price objective (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday. William Blair reaffirmed a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday. Finally, BTIG Research reissued a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.